Literature DB >> 19361262

Reduction in programmed cell death and improvement in functional outcome of transient focal cerebral ischemia after administration of granulocyte-macrophage colony-stimulating factor in rats. Laboratory investigation.

TaeHo Kong1, Jung-Kyoung Choi, Hyeonseon Park, Byung Hyune Choi, Brian Jeffrey Snyder, Shefqat Bukhari, Na-Kyeong Kim, Xian Huang, So Ra Park, Hyung Chun Park, Yoon Ha.   

Abstract

OBJECT: Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a potent hematopoietic growth factor that both enhances the survival and drives the differentiation and proliferation of myeloid lineage cells. Recent studies have suggested that GM-CSF has a neuroprotective effect against CNS injury. In this paper, the authors investigated the neuroprotective effect of GM-CSF on neuron survival and locomotor behavior in a rat model of focal cerebral ischemic injury. MATERIALS: To understand its neuroprotective effect in vitro, GM-CSF was administered to a glutamate-induced excitotoxicity neuronal injury cell culture model that mimics the pathophysiology of focal hypoxic cerebral injury. In the animal study, the authors prepared a rat focal cerebral ischemia model by occluding the unilateral middle cerebral artery. They then examined the effects of GM-CSF administration on changes in infarct volume, apoptosis-related gene expression, and improvement in locomotor behavior.
RESULTS: Treatment with GM-CSF significantly increased cell viability in a cell culture model of glutamate-induced neuronal injury. Furthermore, in vivo administration of GM-CSF at 60 microg/kg body weight daily for 5 consecutive days beginning immediately after injury decreased infarction volume, altered the expression of several apoptosis-related genes (Bcl-2, Bax, caspase 3, and p53), and improved locomotor behavior in the focal cerebral ischemia model.
CONCLUSIONS: The GM-CSF had neuroprotective effects in in vitro and in vivo experiments and resulted in decreased infarction volume and improved locomotor behavior. Although the specific mechanism involved in stroke recovery was not fully elucidated as it was not the primary focus of this study, administration of GM-CSF appeared to decrease the extent of neuronal apoptosis by modulating the expression of several apoptosis-related genes such as Bcl-2, Bax, caspase 3, and p53. Further investigations are necessary to better understand the role of GM-CSF on neural regeneration during the recovery phase of a stroke, as well as the intracellular signal transduction pathways that mediate neuroprotection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19361262     DOI: 10.3171/2008.12.JNS08172

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  25 in total

1.  pH responsive granulocyte colony-stimulating factor variants with implications for treating Alzheimer's disease and other central nervous system disorders.

Authors:  Pete Heinzelman; Jennifer A Schoborg; Michael C Jewett
Journal:  Protein Eng Des Sel       Date:  2015-04-15       Impact factor: 1.650

Review 2.  Bridge between neuroimmunity and traumatic brain injury.

Authors:  Matthew L Kelso; Howard E Gendelman
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

3.  Granulocyte macrophage colony-stimulating factor shows anti-apoptotic activity via the PI3K-NF-κB-HIF-1α-survivin pathway in mouse neural progenitor cells.

Authors:  Jung Kyoung Choi; Kil Hwan Kim; So Ra Park; Byung Hyune Choi
Journal:  Mol Neurobiol       Date:  2013-09-11       Impact factor: 5.590

Review 4.  Role of the β Common (βc) Family of Cytokines in Health and Disease.

Authors:  Timothy R Hercus; Winnie L T Kan; Sophie E Broughton; Denis Tvorogov; Hayley S Ramshaw; Jarrod J Sandow; Tracy L Nero; Urmi Dhagat; Emma J Thompson; Karen S Cheung Tung Shing; Duncan R McKenzie; Nicholas J Wilson; Catherine M Owczarek; Gino Vairo; Andrew D Nash; Vinay Tergaonkar; Timothy Hughes; Paul G Ekert; Michael S Samuel; Claudine S Bonder; Michele A Grimbaldeston; Michael W Parker; Angel F Lopez
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

5.  VEGF induces neuroglial differentiation in bone marrow-derived stem cells and promotes microglia conversion following mobilization with GM-CSF.

Authors:  Bat-Chen R Avraham-Lubin; Nitza Goldenberg-Cohen; Tamilla Sadikov; Nadir Askenasy
Journal:  Stem Cell Rev Rep       Date:  2012-12       Impact factor: 5.739

6.  Distribution of granulocyte-monocyte colony-stimulating factor and its receptor α-subunit in the adult human brain with specific reference to Alzheimer's disease.

Authors:  Sami Ridwan; Henrike Bauer; Katrin Frauenknecht; Harald von Pein; Clemens J Sommer
Journal:  J Neural Transm (Vienna)       Date:  2012-03-20       Impact factor: 3.575

7.  Erythropoietin increases neuronal NDPKA expression, and NDPKA up-regulation as well as exogenous application protects cortical neurons from in vitro ischemia-related insults.

Authors:  Jonathan Teoh; Sherif Boulos; Joanne Chieng; Neville W Knuckey; Bruno P Meloni
Journal:  Cell Mol Neurobiol       Date:  2014-01-07       Impact factor: 5.046

8.  Toll-like receptor 4 contributes to poor outcome after intracerebral hemorrhage.

Authors:  Lauren H Sansing; Tajie H Harris; Frank A Welsh; Scott E Kasner; Christopher A Hunter; Katalin Kariko
Journal:  Ann Neurol       Date:  2011-10       Impact factor: 10.422

9.  Characterization of a Long-Acting Site-Specific PEGylated Murine GM-CSF Analog and Analysis of Its Hematopoietic Properties in Normal and Cyclophosphamide-Treated Neutropenic Rats.

Authors:  George N Cox; Ji I Lee; Mary S Rosendahl; Elizabeth A Chlipala; Daniel H Doherty
Journal:  Protein J       Date:  2020-04       Impact factor: 2.371

Review 10.  Exosomal biomarkers in Down syndrome and Alzheimer's disease.

Authors:  Eric D Hamlett; Aurélie Ledreux; Huntington Potter; Heidi J Chial; David Patterson; Joaquin M Espinosa; Brianne M Bettcher; Ann-Charlotte Granholm
Journal:  Free Radic Biol Med       Date:  2017-09-05       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.